152 related articles for article (PubMed ID: 36220879)
21. Gal-3BP Negatively Regulates NF-κB Signaling by Inhibiting the Activation of TAK1.
Hong CS; Park MR; Sun EG; Choi W; Hwang JE; Bae WK; Rhee JH; Cho SH; Chung IJ
Front Immunol; 2019; 10():1760. PubMed ID: 31402917
[TBL] [Abstract][Full Text] [Related]
22. Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection.
Yeung ST; Premeaux TA; Du L; Niki T; Pillai SK; Khanna KM; Ndhlovu LC
Front Immunol; 2022; 13():1011185. PubMed ID: 36325323
[TBL] [Abstract][Full Text] [Related]
23. Downregulating galectin-3 inhibits proinflammatory cytokine production by human monocyte-derived dendritic cells via RNA interference.
Chen SS; Sun LW; Brickner H; Sun PQ
Cell Immunol; 2015 Mar; 294(1):44-53. PubMed ID: 25684095
[TBL] [Abstract][Full Text] [Related]
24. Galectin-3 Plays an Important Pro-inflammatory Role in the Induction Phase of Acute Colitis by Promoting Activation of NLRP3 Inflammasome and Production of IL-1β in Macrophages.
Simovic Markovic B; Nikolic A; Gazdic M; Bojic S; Vucicevic L; Kosic M; Mitrovic S; Milosavljevic M; Besra G; Trajkovic V; Arsenijevic N; Lukic ML; Volarevic V
J Crohns Colitis; 2016 May; 10(5):593-606. PubMed ID: 26786981
[TBL] [Abstract][Full Text] [Related]
25. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
[TBL] [Abstract][Full Text] [Related]
26. A novel anti-human IL-1R7 antibody reduces IL-18-mediated inflammatory signaling.
Li S; Jiang L; Beckmann K; Højen JF; Pessara U; Powers NE; de Graaf DM; Azam T; Lindenberger J; Eisenmesser EZ; Fischer S; Dinarello CA
J Biol Chem; 2021; 296():100630. PubMed ID: 33823154
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic application of estrogen for COVID-19: Attenuation of SARS-CoV-2 spike protein and IL-6 stimulated, ACE2-dependent NOX2 activation, ROS production and MCP-1 upregulation in endothelial cells.
Youn JY; Zhang Y; Wu Y; Cannesson M; Cai H
Redox Biol; 2021 Oct; 46():102099. PubMed ID: 34509916
[TBL] [Abstract][Full Text] [Related]
28. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein.
Gasparello J; D'Aversa E; Papi C; Gambari L; Grigolo B; Borgatti M; Finotti A; Gambari R
Phytomedicine; 2021 Jul; 87():153583. PubMed ID: 34033999
[TBL] [Abstract][Full Text] [Related]
29. Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus.
Faustini F; Idborg H; Fuzzi E; Larsson A; Lie WR; Pötzsch S; Okitsu SL; Svenungsson E; Gunnarsson I
Lupus; 2023 Feb; 32(2):252-262. PubMed ID: 36508734
[TBL] [Abstract][Full Text] [Related]
30. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
31. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
32. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
33. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
34. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
35. Galectin-3 as an important prognostic marker for COVID-19 severity.
Gajovic N; Markovic SS; Jurisevic M; Jovanovic M; Arsenijevic N; Mijailovic Z; Jovanovic M; Jovanovic I
Sci Rep; 2023 Jan; 13(1):1460. PubMed ID: 36702907
[TBL] [Abstract][Full Text] [Related]
36. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
37. Galectin-3 promotes lamellipodia formation in epithelial cells by interacting with complex N-glycans on alpha3beta1 integrin.
Saravanan C; Liu FT; Gipson IK; Panjwani N
J Cell Sci; 2009 Oct; 122(Pt 20):3684-93. PubMed ID: 19755493
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the Effects of Curcumin on the Cytokine Storm in COVID-19 Using a Chip-Based Multiplex Analysis.
Zahedipour F; Guest PC; Majeed M; Moallem SA; Kesharwani P; Jamialahmadi T; Sahebkar A
Methods Mol Biol; 2022; 2511():285-295. PubMed ID: 35838968
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
40. SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions.
Asrani P; Hassan MI
Mol Cell Biochem; 2021 Feb; 476(2):675-687. PubMed ID: 33064288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
